Implantation of Lactobacillus casei var rhamnosus into vagina

Reid, Gregor; Millsap, Kevin W.; Bruce, AndrewW.

doi:10.1016/s0140-6736(94)90543-6

Cited by 78 publications

(33 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While previous studies in our laboratory have shown that vaginal insertion of GR-1 and B-54 (a strain almost identical to RC-14) leads to colonization of the vaginal tract and prevention of infection in women with acute or recurrent urinary tract infections (4, 5, 21, 24), probiotic identification was based on the Gram staining result and colony morphology only. Molecular biology-based methods have also been used for identification of these strains, with ribotyping used to identify GR-1 in the vagina of one patient following vaginal instillation (22) and to detect RC-14 and GR-1 vaginally following oral administration (20). The RAPD method has also been used to monitor the survival of RC-14 and GR-1 in the human intestine (12) and to determine the survival of other probiotic lactobacilli in dairy products (10).…”

Section: Resultsmentioning

confidence: 99%

Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but Not L. rhamnosus GG in the Human Vagina as Demonstrated by Randomly Amplified Polymorphic DNA

Gardiner

Heinemann

Bruce

et al. 2002

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 are well-characterized probiotic strains with efficacy in the prevention and treatment of urogenital infections in women. The aim of the present study was to apply a molecular biology-based methodology for the detection of these strains and L. rhamnosus GG (a commercially available intestinal probiotic) in the human vagina in order to assess probiotic persistence at this site. Ten healthy women inserted vaginally a capsule containing either a combination of strains GR-1 and RC-14 or the GG strain for 3 consecutive nights. Vaginal swabs taken before and at various time points after probiotic insertion were analyzed, and the Lactobacillus flora was assessed by randomly amplified polymorphic DNA (RAPD) analysis. This method generated discrete DNA fingerprints for GR-1, RC-14, and GG and enabled successful detection of these strains in the vagina. Strain GR-1 and/or strain RC-14 was found to persist in the vaginal tract for up to 19 days after vaginal instillation, while L. rhamnosus GG was detectable for up to 5 days postadministration. In conclusion, the fates of probiotic L. rhamnosus and L. fermentum strains were successfully monitored in the human vagina by RAPD analysis. This technique provides molecular biology-based evidence that RC-14 and GR-1, strains selected as urogenital probiotics, persist in the human vagina and may be more suited to vaginal colonization than L. rhamnosus GG. This highlights the importance of proper selection of strains for urogenital probiotic applications.The vaginal ecosystem is a complex environment in which lactobacilli are the most predominant bacterial species in healthy women (30). A recent study showed that this microflora changes constantly, with only 22% of women having a normal Lactobacillus-dominated flora at any given time (27). As depletion of vaginal lactobacilli can have serious consequences, including increasing the risk of preterm labor and susceptibility to infections such as Neisseria gonorrhoeae, Trichomonas vaginalis, human immunodeficiency virus, and urinary tract infections, bacterial vaginosis, and yeast vaginitis (2,28,30), restoration and maintenance of a normal microflora are important.While antibiotics can be effective for eradication of urinary tract infections, they are often unable to cure bacterial vaginosis or prevent complications that arise from it (6). Furthermore, antibiotics have many side effects, multidrug-resistant microorganisms are common, and such chemotherapeutic agents ideally should not be used for prophylaxis or health maintenance.The use of probiotics, defined as "microbial cell preparations or components of microbial cells that have a beneficial effect on health and well being of the host" (25), offers a potential alternative approach to health restoration and maintenance in the vaginal tract (2,16,29). The question becomes which probiotic strains will persist in and colonize the vagina, given that the vaginal microflora fluctuates daily in terms of both the types and the numbers of...

show abstract

Section: Resultsmentioning

confidence: 99%

Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but Not L. rhamnosus GG in the Human Vagina as Demonstrated by Randomly Amplified Polymorphic DNA

Gardiner

Heinemann

Bruce

et al. 2002

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Further studies with vaginal Lactobacillus treatment of bacterial vaginosis that are more likely to deliver lactobacilli in higher numbers and more quickly than oral ingestion are warranted. Indeed, certain Lactobacillus strains, including L. crispatus CTV05, L. rhamnosus GR-1, and L. fermentum RC-14, are able to remain in the vagina for several months after insertion (18,118).…”

Section: Womens Reproductive and Bladder Healthmentioning

confidence: 99%

Potential Uses of Probiotics in Clinical Practice

Reid

Jaß

Sebulsky³

et al. 2003

Clin Microbiol Rev

Self Cite

735

450

View full text Add to dashboard Cite

Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. There is now mounting evidence that selected probiotic strains can provide health benefits to their human hosts. Numerous clinical trials show that certain strains can improve the outcome of intestinal infections by reducing the duration of diarrhea. Further investigations have shown benefits in reducing the recurrence of urogenital infections in women, while promising studies in cancer and allergies require research into the mechanisms of activity for particular strains and better-designed trials. At present, only a small percentage of physicians either know of probiotics or understand their potential applicability to patient care. Thus, probiotics are not yet part of the clinical arsenal for prevention and treatment of disease or maintenance of health. The establishment of accepted standards and guidelines, proposed by the Food and Agriculture Organization of the United Nations and the World Health Organization, represents a key step in ensuring that reliable products with suitable, informative health claims become available. Based upon the evidence to date, future advances with single- and multiple-strain therapies are on the horizon for the management of a number of debilitating and even fatal conditions

show abstract

“…Reid et al observed that a vaginal application of Lactobacillus casei sub-rhamnosus was able to survive in vagina after 7 weeks of exogenous application concluding that "it was surprising and it was the first and unique observation referring to exogenously-applied Lactobacilli vaginal application" [100].…”

Section: Biotherapeutic Agents Have Been Defined By Mcfarland and Elmmentioning

confidence: 99%

“…Consistently with this information, a lot of clinical trials have recently been performed by using vaginal commercial probiotics containing selected Lactobacillus rhamnosus spp [100][101][102][103][104][105][106][107][108][109].…”

Section: Biotherapeutic Agents Have Been Defined By Mcfarland and Elmmentioning

confidence: 99%

Bacterial Vaginosis and Sexually Transmitted Diseases: Relationship and Management

Bertini¹

2017

Fundamentals of Sexually Transmitted Infections

View full text Add to dashboard Cite

In the last few decades, bacterial vaginosis (BV) has become an emerging pathology; its relationship with pregnancy, pelvic inflammatory disease (PID), infertility, preterm delivery, and neonatal small for gestational age are well established. BV substantially changes vaginal microbiome and these modifications could facilitate sexually transmitted infections (STIs). Several studies have reported an association between abnormal vaginal microbiota, in particular, BV and depletion of lactobacilli species, and increased risk of sexually transmitted infections (STIs) acquisition. Immunologic, enzymatic, and metabolic mechanisms could operate independently or in combination to enhance STIs' transmission. Several studies have pointed out this association: vaginal microbiome modifications in BV could predispose to sexually transmitted diseases (STDs). Considering the high social impact of BV together with its relationship with STDs, it seems to be "crucial" to restore vaginal microbiome in childbearing age women in order to reduce STIs acquisition. Some experimental clinical data seem to confirm this observation: vaginal microbiome restoration by probiotics/synbiotics seems to improve not only STIs' acquisition but also STDs' pathology progression. Restoring vaginal microbiome could represent an international, innovative, and less-expensive gold standard to counteract STDs' spread and acquisition.

show abstract

Implantation of Lactobacillus casei var rhamnosus into vagina

Cited by 78 publications

References 4 publications

Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but Not L. rhamnosus GG in the Human Vagina as Demonstrated by Randomly Amplified Polymorphic DNA

Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but Not L. rhamnosus GG in the Human Vagina as Demonstrated by Randomly Amplified Polymorphic DNA

Potential Uses of Probiotics in Clinical Practice

Bacterial Vaginosis and Sexually Transmitted Diseases: Relationship and Management

Contact Info

Product

Resources

About